Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
about
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an updateInduction of premature senescence by hsp90 inhibition in small cell lung cancerPhase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancerDevelopment and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance.P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangementTumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.Development of target-specific treatments in multiple myeloma.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression.Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.Recent advances in nanomedicine and survivin targeting in brain cancers.A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells.
P2860
Q28272905-09E08D63-8628-4256-9A47-F3468314B522Q28474354-D29EA0F7-D705-4724-81A2-527F4D3319C4Q28477773-7AC0B234-A9A6-48F9-94B4-FA07A3BBCBA5Q31039889-D25B599D-5644-4EB4-879E-EA63EFE41D5EQ33632270-C2A5919E-7365-4D65-82DE-E69C1E3B626DQ34268075-C0F04A85-3B9E-47BB-9266-1FCF2433703EQ35098333-3A7DD7DE-2E4C-4B97-8273-B2B56F75B36CQ35542753-9F3B02D4-73F0-46B5-9F6C-5993F0FD38EAQ35720969-D284BEB4-8B0E-4441-A0E1-E0DFDE72A71FQ36465517-784B2383-3348-4C58-BCFC-4E484B1EE242Q36546609-934FF16A-3EAA-4006-A55B-41B86612493CQ37771370-DDB7D34A-8372-4738-9274-55BC4C384BC5Q37827173-925AB751-2C3A-4604-9B02-FD85128CA6B0Q38103907-89C2301E-1BF4-4C9A-8B9F-802D3D9C04C3Q38503345-56FAB9DF-990C-4D61-ADC3-727DACA9D672Q39091969-A9636DB0-9F2D-4538-AB9B-6D49B345B621Q44514465-D4D69C6B-EE5B-4C59-AF91-51A3F1F67D06Q47378913-034B9B90-C769-4A0B-B1CD-DC4F005AAA23Q51638544-7E57885D-F1BB-49DB-816F-C9EA74692A82Q53059131-12CA11CB-EB4F-46B0-8732-6022174613D1Q53636138-E0590DAE-B625-4807-9790-B43A4A2A34F0
P2860
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@en
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@nl
type
label
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@en
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@nl
prefLabel
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@en
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@nl
P2860
P1476
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
@en
P2093
Charles Erlichman
P2860
P304
P356
10.1517/13543780902953699
P407
P577
2009-06-01T00:00:00Z